These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 26048698)

  • 1. The influence of anti-TNF therapy on the magnetic resonance enterographic parameters of Crohn's disease activity.
    Eder P; Katulska K; Krela-Kaźmierczak I; Stawczyk-Eder K; Klimczak K; Szymczak A; Linke K; Łykowska-Szuber L
    Abdom Imaging; 2015 Oct; 40(7):2210-8. PubMed ID: 26048698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn's disease.
    Ordás I; Rimola J; Rodríguez S; Paredes JM; Martínez-Pérez MJ; Blanc E; Arévalo JA; Aduna M; Andreu M; Radosevic A; Ramírez-Morros AM; Pinó S; Gallego M; Jauregui-Amezaga A; Ricart E; Panés J
    Gastroenterology; 2014 Feb; 146(2):374-82.e1. PubMed ID: 24177375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Findings of ulceration and severe stricture on MRE can predict prognosis of Crohn's disease in patients treated with anti-TNF treatment.
    Naganuma M; Okuda S; Hisamatsu T; Matsuoka K; Mori K; Hosoe N; Nakazato Y; Ogata H; Kanai T
    Abdom Radiol (NY); 2017 Jan; 42(1):141-151. PubMed ID: 27549100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of infliximab therapy on transmural lesions as assessed by magnetic resonance enteroclysis in patients with ileal Crohn's disease.
    Van Assche G; Herrmann KA; Louis E; Everett SM; Colombel JF; Rahier JF; Vanbeckevoort D; Meunier P; Tolan D; Ernst O; Rutgeerts P; Vermeire S; Aerden I; Oortwijn A; Ochsenkühn T
    J Crohns Colitis; 2013 Dec; 7(12):950-7. PubMed ID: 23411006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn's disease: correlation with SES-CD and clinical-biological markers.
    Stoppino LP; Della Valle N; Rizzi S; Cleopazzo E; Centola A; Iamele D; Bristogiannis C; Stoppino G; Vinci R; Macarini L
    BMC Med Imaging; 2016 May; 16(1):37. PubMed ID: 27149857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in dynamic contrast-enhanced pharmacokinetic and diffusion-weighted imaging parameters reflect response to anti-TNF therapy in Crohn's disease.
    Bhatnagar G; Dikaios N; Prezzi D; Vega R; Halligan S; Taylor SA
    Br J Radiol; 2015; 88(1055):20150547. PubMed ID: 26402217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-sectional evaluation of transmural healing in patients with Crohn's disease on maintenance treatment with anti-TNF alpha agents.
    Castiglione F; Mainenti P; Testa A; Imperatore N; De Palma GD; Maurea S; Rea M; Nardone OM; Sanges M; Caporaso N; Rispo A
    Dig Liver Dis; 2017 May; 49(5):484-489. PubMed ID: 28292640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Magnetic resonance enterography findings as predictors of clinical outcome following antitumor necrosis factor treatment in small bowel Crohn's disease.
    Gibson DJ; Murphy DJ; Smyth AE; McEvoy SH; Keegan D; Byrne K; Mulcahy HE; Cullen G; Malone DE; Doherty GA
    Eur J Gastroenterol Hepatol; 2015 Aug; 27(8):956-62. PubMed ID: 26049706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnetic resonance enterographic predictors of one-year outcome in ileal and ileocolonic Crohn's disease treated with anti-tumor necrosis factor antibodies.
    Eder P; Michalak M; Katulska K; Lykowska-Szuber L; Krela-Kazmierczak I; Stawczyk-Eder K; Klimczak K; Szymczak A; Linke K
    Sci Rep; 2015 May; 5():10223. PubMed ID: 25993615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of anti-TNF therapy on CD31 and VEGF expression in colonic mucosa of Crohn's disease patients in relation to mucosal healing.
    Eder P; Lykowska-Szuber L; Iwanik K; Krela-Kazmierczak I; Stawczyk-Eder K; Majewski P; Linke K; Kay EW; Wozniak A
    Folia Histochem Cytobiol; 2016; 54(2):75-80. PubMed ID: 27270504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trefoil factor-3 is not a useful marker of mucosal healing in Crohn's disease treated with anti-TNF-α antibodies.
    Eder P; Stawczyk-Eder K; Korybalska K; Czepulis N; Luczak J; Lykowska-Szuber L; Krela-Kazmierczak I; Linke K; Witowski J
    World J Gastroenterol; 2017 Jan; 23(1):135-140. PubMed ID: 28104989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diffusion-weighted magnetic resonance enterocolonography in predicting remission after anti-TNF induction therapy in Crohn's disease.
    Buisson A; Hordonneau C; Goutte M; Scanzi J; Goutorbe F; Klotz T; Boyer L; Pereira B; Bommelaer G
    Dig Liver Dis; 2016 Mar; 48(3):260-6. PubMed ID: 26699828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of tumor necrosis factor-α antagonists on oxidative stress in patients with Crohn's disease.
    Yamamoto K; Chiba T; Matsumoto T
    World J Gastroenterol; 2015 Sep; 21(35):10208-14. PubMed ID: 26401086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small-Bowel Crohn Disease Treated With Anti-Tumor Necrosis Factor-α Therapy: MR Enterography Score Changes After 1 Year Predict Long-Term Outcomes.
    Gallego JC; de Juan C; Echarri A; Lopez-de-Ullibarri I
    AJR Am J Roentgenol; 2019 Dec; 213(6):1240-1246. PubMed ID: 31414894
    [No Abstract]   [Full Text] [Related]  

  • 15. Endoscopic response to tumor necrosis factor inhibitors predicts long term benefits in Crohn's disease.
    Alfaro I; Masamunt MC; Planell N; López-García A; Castro J; Gallego M; Barastegui R; Giner A; Vara A; Salas A; Ricart E; Panés J; Ordás I
    World J Gastroenterol; 2019 Apr; 25(14):1764-1774. PubMed ID: 31011260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-treatment magnetic resonance enterography findings predict the response to TNF-alpha inhibitors in Crohn's disease.
    Rimola J; Fernàndez-Clotet A; Capozzi N; Rojas-Farreras S; Alfaro I; Rodríguez S; Masamunt MC; Ricart E; Ordás I; Panés J
    Aliment Pharmacol Ther; 2020 Nov; 52(10):1563-1573. PubMed ID: 32886809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-TNF Therapy Within 2 Years of Crohn's Disease Diagnosis Improves Patient Outcomes: A Retrospective Cohort Study.
    Ma C; Beilman CL; Huang VW; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    Inflamm Bowel Dis; 2016 Apr; 22(4):870-9. PubMed ID: 26818419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease.
    af Björkesten CG; Nieminen U; Sipponen T; Turunen U; Arkkila P; Färkkilä M
    Scand J Gastroenterol; 2013 May; 48(5):543-51. PubMed ID: 23477356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective assessment of the effect on quality of life of anti-tumour necrosis factor therapy for perineal Crohn's fistulas.
    Ng SC; Plamondon S; Gupta A; Burling D; Kamm MA
    Aliment Pharmacol Ther; 2009 Oct; 30(7):757-66. PubMed ID: 19575762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fourteen-Year Anti-TNF Therapy in Crohn's Disease Patients: Clinical Characteristics and Predictive Factors.
    Osamura A; Suzuki Y
    Dig Dis Sci; 2018 Jan; 63(1):204-208. PubMed ID: 29209921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.